Drugs in ATC Class A04AD

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Up to A04 - ANTIEMETICS AND ANTINAUSEANTS

Up to A04A - ANTIEMETICS AND ANTINAUSEANTS

Drugs in ATC Class: A04AD - Other antiemetics

Tradename	Generic Name
METHSCOPOLAMINE BROMIDE	methscopolamine bromide
PAMINE	methscopolamine bromide
PAMINE FORTE	methscopolamine bromide

A04AD Market Analysis and Financial Projection

The ATC Class A04AD - Other Antiemetics encompasses a diverse group of medications used to manage nausea and vomiting, including neurokinin-1 (NK1) receptor antagonists, cannabinoids, and other agents. Here's an analysis of its market dynamics and patent landscape:

---

Market Dynamics

Growth Drivers

1. Rising Cancer Prevalence: Chemotherapy-induced nausea and vomiting (CINV) remains a key driver, with antiemetics like aprepitant preventing CINV in 60–70% of patients[3][4][20]. The global antiemetics market is projected to grow from $8.45B in 2025 to $9.7B by 2029 at a 3.5% CAGR[3][4].
2. Surgical Procedures: Postoperative nausea and vomiting (PONV) increases demand, especially for drugs like scopolamine and aprepitant[8][20].
3. Innovations in Drug Delivery: Ready-to-use injectables (e.g., Amneal’s FOCINVEZ) and sustainable nasal sprays (e.g., Aptar Pharma’s APF Futurity) enhance compliance and market differentiation[3][23].
4. Personalized Medicine: Genetic targeting, as seen in Adial Pharmaceuticals’ AD04 for alcohol use disorder, underscores advancements in precision therapies[12].

Market Segmentation

• By Application: CINV dominates, accounting for $3.1B in 2023[8].
• By Region: North America leads with 2023 revenues of $4.2B, driven by high cancer rates and healthcare spending[14][18].

Key Trends

• Non-invasive Treatments: Preference for oral and transdermal formulations[8][14].
• Sustainability Focus: Recyclable packaging and metal-free devices gain traction[3].

---

Patent Landscape

Key Drugs and Patents

• Aprepitant:
  • Brands: Emend (Merck), Cinvanti (Heron Therapeutics)[2][10].
  • Patents: 14 U.S. patents protecting formulations and uses, with expiries extending to 2035[2][7][10]. Notable litigation includes four Paragraph IV challenges[16].
  • Market Impact: Aprepitant’s 2023 sales contributed significantly to the neurokinin antagonist segment, projected to grow at 6.2% CAGR[20].

Competitive Strategies

• Generic Entry: Aprepitant faces competition from generics by Glenmark, Sandoz, and Torrent[2][16].
• Innovation: New NK1 antagonists like rolapitant and casopitant expand the pipeline[9][10].

Regulatory and Economic Factors

• Reimbursement Policies: Drugs like FOCINVEZ receive J-Code assignments (e.g., J1434), streamlining insurance claims[3].
• Cost Pressures: Price compliance reviews, such as Canada’s PMPRB guidelines, ensure affordability post-patent expiry[10][11].

---

Future Outlook

The A04AD market will likely see:

1. Biologics and Targeted Therapies: Enhanced efficacy in managing refractory CINV[14][20].
2. Biosimilar Competition: Post-2035, aprepitant generics may reduce prices by 30–40%[2][16].
3. Asia-Pacific Expansion: Rising healthcare investments in China and India drive a projected 7.8% regional CAGR[23].

---

Highlight: "The integration of pharmacogenomics into antiemetic development is revolutionizing personalized care, particularly in oncology"[12][20].

This evolving landscape underscores the interplay between innovation, regulatory shifts, and unmet clinical needs in shaping the A04AD market.

References

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC4976915/
2. https://www.drugpatentwatch.com/p/generic/aprepitant
3. https://www.thebusinessresearchcompany.com/report/antiemetics-and-antinauseants-global-market-report
4. https://www.researchandmarkets.com/reports/5735380/antiemetics-antinauseants-market-report
5. https://en.wikipedia.org/wiki/ATC_code_A04
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8359203/
7. https://go.drugbank.com/drugs/DB00673
8. https://www.gminsights.com/industry-analysis/antiemetics-drugs-market
9. https://en.wikipedia.org/wiki/ATC_code_A04
10. http://www.pmprb-cepmb.gc.ca/view.asp?ccid=604
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4976915/
12. https://www.globenewswire.com/news-release/2024/12/03/2990626/26135/en/Adial-Pharmaceuticals-Granted-Key-U-S-Patent-for-the-Treatment-of-Alcohol-and-Drug-Dependence-Based-on-Expanded-Genotype-Combinations.html
13. https://www.iqvia.com/-/media/iqvia/pdfs/belgium/sales-trends/2020/may-belgian-reg-med-best.pdf
14. https://www.globenewswire.com/news-release/2024/10/10/2961576/0/en/Global-Antiemetics-Drugs-Market-to-Exhibit-Growth-at-a-CAGR-of-6-by-2030-DelveInsight.html
15. https://www.kegg.jp/entry/D07103
16. https://www.drugpatentwatch.com/p/generic/aprepitant
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC4976915/
18. https://www.globenewswire.com/news-release/2024/10/10/2961576/0/en/Global-Antiemetics-Drugs-Market-to-Exhibit-Growth-at-a-CAGR-of-6-by-2030-DelveInsight.html
19. https://research.rug.nl/files/179142792/Trends_in_polypharmacy_and_potentially_inappropriate.pdf
20. https://www.globenewswire.com/news-release/2024/08/27/2936055/28124/en/Antiemetic-Drugs-Strategic-Research-Report-2024-2030-Pharmacogenomics-and-Personalized-Medicine-Shape-the-Future-of-Developments-Rising-Cancer-Rates-and-Chemotherapy-Demand-Fuel-Ex.html
21. https://vvkt.lrv.lt/media/viesa/saugykla/2023/9/nvNsI8S7K9U.pdf
22. https://www.grandviewresearch.com/industry-analysis/antiemetics-drugs-market-report
23. https://www.alliedmarketresearch.com/antiemetics-market